Bengaluru, Aug 6: Biocon Limited, an innovation-led global biopharmaceuticals company, announced its consolidated financial results for the fiscal first quarter ended June 30, 2026.
|
FINANCIAL PERFORMANCE
|
|
|
“Biocon has entered FY27 with a clear focus on translating our strategic investments into sustainable growth and long-term value creation. A favourable policy environment for biosimilars together with our expanded manufacturing capabilities in the U.S. reinforce our confidence in the long-term opportunities across North America, our biggest market. We also remain confident that the investments in new capabilities at our research services business will support its next phase of growth.”– Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited
“Biocon delivered a resilient performance in Q1FY27, reporting consolidated revenue from operations growth of 10% year-on-year to Rs 4,336 crore and EBITDA of Rs 902 crore. This reflects the strength of our diversified portfolio and disciplined commercial execution. In FY27, we have successfully launched Bosaya™️ and Aukelso (biosimilar Denosumab), Yesafili (biosimilar Aflibercept), and generic Liraglutide, further strengthening our presence in the U.S. market. We also secured regulatory approval from the European Medicines Agency (EMA) for our new drug product fill-finish plant for insulins in Malaysia, unlocking additional manufacturing capacity. Our focus on balance sheet optimization reduced interest costs by 23% year-on-year. We expect growth momentum to accelerate through the year, driving a stronger second-half performance.”– Shreehas Tambe, CEO & Managing Director, Biocon Limited
“As I take charge of Syngene, amid headwinds that the Company is currently navigating, I look forward to working closely with the Board and our leadership team to sharpen our focus and translate our priorities into tangible business outcomes that will provide a strong foundation for long-term growth.
My immediate priorities are to sharpen our commercial execution, strengthen delivery across our businesses, and build a more agile, cost-competitive organization. At the same time, we will continue to invest in CDMO, AI, innovation and differentiated scientific capabilities that will strengthen our competitive position.” – Siddharth Mittal, CEO & Managing Director, Syngene International Limited
FINANCIAL HIGHLIGHTS : Q1FY27
In Rs Crore
|
Particulars |
Q1FY27 |
Q1FY26 |
YoY (%) |
|
INCOME |
|||
|
Biosimilars |
2,855 |
2,458 |
16% |
|
Generics |
760 |
630 |
21% |
|
Biopharma |
3,615 |
3,088 |
17% |
|
Services |
736 |
875 |
(16%) |
|
Inter-segment |
(15) |
(21) |
28% |
|
Revenue from operations# |
4,336 |
3,942 |
10% |
|
Other income |
55 |
80 |
(31%) |
|
Total Income |
4,391 |
4,022 |
9% |
|
Net R&D Expenses |
240 |
205 |
17% |
|
EBITDA |
902 |
846 |
7% |
|
EBITDA Margins |
21% |
21% |
|
|
PBT |
141 |
114 |
24% |
|
PBT |
128 |
97 |
32% |
|
Net Profit |
145 |
42 |
245% |
|
Net Profit |
141 |
31 |
355% |
BUSINESS PERFORMANCE – Biopharma
North America
- Growth in North America region was driven by the ramp-up of recently launched biosimilars, including Bosaya and Aukelso in the U.S., coupled with stable performance in the oncology portfolio.
- Commercialized Yesafili in the U.S., in August, as an interchangeable biosimilar Aflibercept.
- Secured Health Canada Notice of Compliance for Yesintek autoinjector pen.
- Commercialized generic Liraglutide in the U.S.
Europe
- Commercialized Evfraxy, for bone health, across multiple European markets.
- Commercialized Abevmy from oncology portfolio in Czech Republic and Switzerland.
Emerging Markets
- Expanded market access through multiple product approvals and commercial partnerships across Emerging Market countries.
- Secured approval for Yesafili™ as Malaysia’s first biosimilar Aflibercept.
- Maintained strong market leadership for biosimilar Bevacizumab franchise in Brazil.
BUSINESS PERFORMANCE – Services
- Signed MoU with BRIC-Translational Health Science and Technology Institute for early and late-phase clinical development, translational research, and bioanalytical sciences. The collaboration will enable the evaluation and execution of First-in-Human and Phase I clinical programs, along with bioanalytical, biomarker and patient-based clinical research programs.
- Continued to strengthen Syn.AI, an AI-enabled scientific platform for accelerating drug discovery services, by developing giga scale virtual screening capabilities. This will enable screening and prioritizing larger libraries of molecules, accelerating the identification of promising drug candidates.
Board Updates
- Bobby Parikh has completed his term as an Independent Director of the Company with effect from the close of business hours of July 22, 2026.
- Nicholas Haggar shall complete his term as an Independent Director of the Company with effect from the conclusion of the ensuing 48th Annual General Meeting of the Company scheduled to be held on August 6, 2026.
- The Board places on record its appreciation for their valuable services and contributions during their tenure with the Company.
Awards and Recognitions
- Kiran Mazumdar-Shaw ranked No. 4 in ‘Biopharma’ category on The Global Medicine Maker Power List 2026.
- Kiran Mazumdar-Shaw recognized for ‘Lifetime Contribution to UK-India Relations’ at the 10th edition of India Global Forum’s UK-India Week.
- Kiran Mazumdar-Shaw ranked No. 6 on Fortune India’s 100 Most Powerful Women 2026 list.
- Biocon recognized as a trailblazing brand at the 8th ET NOW’s Iconic Brands of India.
Sustainability / ESG
- Biocon’s Bio-Pure Project recognized with the ‘Sustainability Initiative of the Year’ Award 2026 by International Health Partners at the Medicines for Europe Conference.
- Biocon recognized as ‘Company of the Year’ at the Sustainability & CSR Malaysia Awards 2026, marking its third consecutive win.
